Radioprotective properties of histamine H2 receptor antagonists: Present and future prospects

Journal of Radiation Research

Volumn 44, Issue 2, 2003, Pages 145-149

  Mozdarani, Hossein ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Chromosomal aberration; H2 receptor antagonist; Micronuclei; Radioprotection

Indexed keywords

BLOOD; BONE; CHROMOSOMES; DOSIMETRY; DRUG DOSAGE; RADIATION EFFECTS; RADIATION PROTECTION;

CHROMOSOMAL ABERRATION; H2 RECEPTOR ANTAGONIST; HISTAMINES; IN-VITRO; IN-VIVO; MICRONUCLEUS; PROPERTY; RADIATION-INDUCED; RADIOPROTECTION; RECEPTOR ANTAGONISTS;

LYMPHOCYTES;

CIMETIDINE; CLASTOGEN; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; RADIOPROTECTIVE AGENT; RANITIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL ASSAY; CHROMOSOME ABERRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ERYTHROCYTE; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; LYMPHOCYTE; MALE; METAPHASE; MICRONUCLEUS TEST; MOUSE; NONHUMAN; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION;

ANIMALIA;

EID: 2942515144     PISSN: 04493060     EISSN: None     Source Type: Journal    
DOI: 10.1269/jrr.44.145     Document Type: Article

References (29)

1. Patt, H. M., Mayer, S. H., Strabe, R. L. and Jackson, E. M. (1953) Radiation dose reduction by cysteine. J. Cell Comp. Physiol. 42: 327-341.
2. Davidson, D. E, Greman, M. M. and Seeney, T. R. (1980) Radiological characterization of some improved radioprotectors. In: Radiation Sensitisers; Their Use in the Clinical Management of Cancer, Ed. L. W. Brady, pp: 309-320, Masson, New York.
3. Durand, R. E. (1983) Radioprotection by WR2721 in vivo at low oxygen tension: implication for its mechanisms and actions. Br. J. Cancer 47: 387-392.
4. Maisin, J. R. (1998) Chemical radioprotection. Past, present and future prospects. Int. J. Radiat. Biol. 73: 443-450.
5. Yuhas, J. M. and Storer, J. B. (1969) Differential chemoprotection of normal and malignant tissues. J. Natl. Cancer Inst. 42: 331-335.
6. Murray, D. and McBride, W. H. (1996) Radioprotective Agents: in Kirk-Othmer Encyclopedia of Clinical Technology, 4th ed. Vol. 20, pp. 963-1006. John Wiley and Sons, Chichester.
7. Bors, W., Heller, W., Michel, C. and Saran, M. (1990) Flavonoids as antioxidants: Determination of radical scavenging efficiencies. Methods Enzymol. 186: 343-355.
8. Steven, J. F., Miranda, C. L. and Buhler, D. R. (1998) Chemistry and biology of hop flavonoids. J. Am. Soc. Brew. Chem. 56: 136-145.
9. Castillo, J., Gracia, O. B. and Lorente, J. (2000) Antioxidant activity and radioprotective effects against chromosomal damage induced in vivo by X-rays of flavan-3-ols (procyanidins) from grapes seeds (Vitis Vinifera): Comparative study versus other phenolic and organic compounds. J. Agric. Food Chem. 48: 1738-1745.
10. Koleva, I., Vanbeek, T. A. and Lissen, J. P. (2002) Screening of plant extracts for antioxidant activity: a comparative study on three testing methods. Phytochem. Anal. 13: 8-17.
11. Hosseinmehr, S. J., Shafiee, A., Mozdarani, H. and Akhlaghpour, S. (2001) Radioprotective effects of 2-iminothiazolidine derivatives against lethal doses of gamma radiation in mice. J. Radiat. Res. 42: 401-408.
12. Hosseinmehr, S. J., Shafiee, A., Mozdarani, H., Akhlaghpour, S. and Froughizadeh M. (2002) Radioprotective effects of 2-imino-3-[(chromone-2-yl) carbonyl] thiazolidines against lethal doses of gamma radiation in mice. J. Radiat. Res. 43: 293-300.
13. Bardhan, K. D. (1981) Histamine H2 receptor antagonists. In: Prospective in Duodenal Ulcer, 2nd ed., Ed. S. pp. 73-84. Kline and French. Hertfordshire.
14. Mozdarani, H. and Vessal, N. J. (1993) Cimetidine can modify the effects of whole body gamma irradiation on lymphohematopoetic systems. Med. J. IR. Iran 7: 95-99.
15. Mozdarani, H. and Gharbali, A. (1993) Radioprotective effects of cimetidine in mouse bone marrow cells exposed to gamma rays as assayed by the micronucleus test. Int. J. Radiat. Biol. 64: 189-194.
16. Mozdarani, H. and Khoshbin-khoshnazar, A. (1998) In vivo protection against fast neutron induced micronuclei in mouse bone marrow cells. Cancer Lett. 124: 65-71.
17. Schmid, W. (1975) The micronucleus test. Mutat. Res. 31: 9-15.
18. Ching, T. L., Jong, J. D. and Bast A. (1994) Structural characteristics of histamine H2 receptor antagonists that scavenge hypochlorous acid. Eur. J. Pharm. 268: 89-93
19. Lapenna, D., Egioia, S., Mezzetti, A. and Grossi, L. (1994) H2 receptor antagonists are scavengers of oxygen radicals. Exp. J. Clin. Invest. 24: 479-481.
20. ISCN (1985) International system of cytogenetic nomenclature for acquired chromosome aberrations. Ed. D. G. Harnden and H. P. Klinger, pp. 66-73, published in collaboration with Cytogenetic Cell Genetics, Karger.
21. Freston, J. W. (1982) Cimetidine. I. Developments, pharmacology, and efficacy. Ann. Intern. Med. 97: 537-580.
22. Parsons, M. E. and Lewin, M. J. M. (1991) Histamine receptors: An overview their affinity of histamine and their second messengers. Scand. J. Gastroentreol. (Suppl.) 108: 46-52.
23. Lipsy, R. J., Fennerty, B. F. and Fagan, T. C. (1990) Clinical review of histamine2 receptor antagonists. Arch. Int. Med. 150: 745-751.
24. Ching, T. L., Haenen, G. R. M. M. and Bast A. (1993) Cimetidine and other H2 receptor antagonists as powerful hydroxyl radical scavengers. Chem. Biol. Interact. 86, 119-127.
25. Halliwell, B. and Gutteridge, J. M. C. (1989) Free Radicals in Biology and Medicine, Clarendon Press, Oxford.
26. Garriott, M. C. and Grow, D. J. (1983) AET reduced the frequency of micronuclei in bone marrow cells of mice exposed to gamma radiation. Rad. Res. 93: 200-204.
27. Murray, R. K., Granner, D. K., Mayes, P. A. and Rodwell, W. (1988) Harper's Biochemistry, pp. 29, 105, 139, 179, 291, 295.
28. Ilyinskikh, N. N. and Ilyinskikh, I. N. (1988) The Using of Micronuclei Test of the Erythrocytes for Screening of Cytogenetic Unstability in Man, Medical Institute USSR, Russia.
29. Gifford, R. R. M. and Vallera, D. A. (1983) Cimetidine induced augmentation of cell mediated cytotoxicity following in vitro and in vivo treatment. Fed., Pro. 39: 924.